We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+59.12%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$8.26B
AUM Growth
+$2.81B
Cap. Flow
+$660M
Cap. Flow %
7.99%
Top 10 Hldgs %
46.78%
Holding
97
New
16
Increased
23
Reduced
35
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$242M
2
STTK icon
Shattuck Labs
STTK
+$181M
3
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$164M
4
ABBV icon
AbbVie
ABBV
+$133M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$91.4M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$275M
2
BNTX icon
BioNTech
BNTX
+$64.3M
3
BSX icon
Boston Scientific
BSX
+$54.3M
4
FOLD
Amicus Therapeutics
FOLD
+$50.2M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$37.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.01%
2 Technology 0.52%
3 Financials 0.46%
4 Consumer Staples 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMED
51
DELISTED
Amedisys
AMED
$39.2M 0.47%
133,480
-6,700
-5% -$1.72M
SLQT icon
52
SelectQuote
SLQT
$127M
$38.3M 0.46%
1,844,719
+489,415
+36% +$10M
QURE icon
53
uniQure
QURE
$2.77B
$37.2M 0.45%
1,028,898
-99,929
-9% -$4.22M
PRAH
54
DELISTED
PRA Health Sciences, Inc.
PRAH
$33.3M 0.4%
265,736
-12,200
-4% -$1.36M
CNC icon
55
Centene
CNC
$32.8B
$33.3M 0.4%
+554,962
New +$35.3M
CTLT
56
DELISTED
CATALENT, INC.
CTLT
$32.7M 0.4%
314,519
-14,900
-5% -$1.44M
RCEL icon
57
Avita Medical
RCEL
$157M
$31.7M 0.38%
1,707,386
-72,200
-4% -$1.58M
PPD
58
DELISTED
PPD, Inc. Common Stock
PPD
$28.2M 0.34%
823,192
-29,900
-4% -$1.04M
ARDX icon
59
Ardelyx
ARDX
$1.28B
$22.7M 0.28%
3,514,100
– –
IMTX icon
60
Immatics
IMTX
$1.31B
$22.3M 0.27%
2,068,301
-61,699
-3% -$651K
PAND
61
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
$20.8M 0.25%
1,398,705
+279,105
+25% +$3.88M
HOOK
62
DELISTED
HOOKIPA Pharma
HOOK
$20.4M 0.25%
184,290
– –
ABCL icon
63
AbCellera Biologics
ABCL
$1.97B
$20.1M 0.24%
+500,000
New +$22.9M
LUNG icon
64
Pulmonx
LUNG
$59.1M
$19M 0.23%
+275,000
New +$13.5M
CABA icon
65
Cabaletta Bio
CABA
$461M
$17.2M 0.21%
1,378,319
-8,265
-0.6% -$107K
PROF
66
Profound Medical
PROF
$249M
$17M 0.21%
825,197
+197
+0% +$3.62K
CTSO icon
67
Cytosorbents Corp
CTSO
$22.6M
$16.4M 0.2%
2,054,131
-47,000
-2% -$393K
STXS icon
68
Stereotaxis
STXS
$154M
$15.8M 0.19%
3,103,327
– –
ITMR
69
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$14.1M 0.17%
711,500
+86,500
+14% +$1.73M
GRTS
70
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$12.1M 0.15%
3,059,794
– –
XERS icon
71
Xeris Biopharma Holdings
XERS
$1.52B
$11.8M 0.14%
2,397,441
– –
SKIN icon
72
SkinHealth Systems
SKIN
$109M
$11.3M 0.14%
+1,000,000
New +$10.8M
KA
73
DELISTED
Kineta, Inc. Common Stock
KA
$10.4M 0.13%
+87,286
New +$13.3M
AYLA
74
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$7.61M 0.09%
667,816
+1,150
+0.2% +$13.3K
SEER icon
75
Seer Inc
SEER
$119M
$7.02M 0.09%
+125,000
New +$7.95M
1 2
3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q4 2020 Portfolio in Review

As of Q4 2020, Redmile Group held 97 positions worth $8.26B, up 52% from $5.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $660M of net new capital in Q4 2020, opening 16 new positions and adding to 23 existing holdings. Its largest new stake was Shattuck Labs: 5,619,914 shares worth $295M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was BioNTech, an estimated $64.3M trimmed.

  • Redmile Group's largest Q4 2020 buy was Shattuck Labs: 5,619,914 shares worth $295M.
  • Redmile Group added most to Invitae Corporation in Q4 2020, an estimated $242M increase.
  • Redmile Group's biggest Q4 2020 reduction was BioNTech, cutting an estimated $64.3M.
  • Redmile Group fully exited Immunomedics Inc in Q4 2020, selling an estimated $275M.
  • Redmile Group's ten largest holdings make up 47% of its $8.26B portfolio in Q4 2020.
  • Redmile Group opened 16 new positions and closed 10 in Q4 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $8.26B.

Based on Redmile Group's 13F filing for Q4 2020, filed 16 Feb 2021.